Helen (Chlormadinone Acetate, Ethinylestradiol)

The ethinylestradiol and chlormadinone acetate in Helen maintain steady hormone levels that block the natural hormonal fluctuations required for the release of an egg, effectively stopping ovulation each cycle.

Smoking more than 15 cigarettes per day in women older than 35 is listed as a precaution for Helen because it increases the risk of thromboembolic events. Healthcare providers usually advise against using combined oral contraceptives in this population.

Common side effects include nausea, breast tenderness, headache, breakthrough spotting, mild weight gain, and occasional mood changes. These effects are usually transient and may improve after the first few cycles.

If pregnancy is confirmed while taking Helen, the tablet should be discontinued immediately. The woman should then discuss prenatal care with her healthcare provider, as continued exposure to hormonal contraceptives is not recommended during pregnancy.

There are no specific dietary restrictions for Helen, but patients should maintain a balanced diet and avoid excessive alcohol consumption, which can increase the risk of liver‑related side effects.

Some antibiotics, particularly tetracyclines, may reduce the enterohepatic recirculation of estrogen, potentially decreasing the contraceptive effectiveness of Helen. Additional non‑hormonal contraception is advised during antibiotic therapy and for a short period after completion.

If a tablet is missed, take it as soon as remembered unless it is close to the time of the next scheduled dose. If two or more consecutive tablets are missed, use a backup method of contraception for the next seven days and consult a healthcare professional.

Concurrent use of Helen with HRT can increase overall hormone exposure and may raise the risk of side effects such as thrombosis. A physician should evaluate the need for combined therapy and monitor the patient closely.

Like all combined estrogen‑progestogen contraceptives, Helen carries a risk of venous thromboembolism, especially in women with pre‑existing risk factors such as smoking, obesity, or a personal/family history of clotting disorders.

Initial follow‑up is typically scheduled within three months of starting Helen to assess tolerance and blood pressure. Subsequent annual visits are recommended, or sooner if new risk factors develop.

Helen often leads to more regular, lighter periods after the first few cycles. Some women may experience breakthrough spotting or amenorrhea, which should be discussed with a healthcare provider if persistent.